Geode Capital Management LLC Has $41.01 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Geode Capital Management LLC raised its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG) by 2.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,815,710 shares of the company’s stock after buying an additional 42,777 shares during the quarter. Geode Capital Management LLC owned about 1.50% of 10x Genomics worth $41,009,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. ARK Investment Management LLC raised its stake in 10x Genomics by 15.4% during the 3rd quarter. ARK Investment Management LLC now owns 10,750,345 shares of the company’s stock worth $242,743,000 after buying an additional 1,436,582 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of 10x Genomics in the third quarter worth about $27,778,000. Deerfield Management Company L.P. Series C acquired a new stake in shares of 10x Genomics during the second quarter worth about $11,612,000. FMR LLC lifted its holdings in shares of 10x Genomics by 2.7% during the 3rd quarter. FMR LLC now owns 13,367,979 shares of the company’s stock valued at $301,849,000 after purchasing an additional 357,470 shares in the last quarter. Finally, Algert Global LLC grew its position in shares of 10x Genomics by 214.5% in the 3rd quarter. Algert Global LLC now owns 370,958 shares of the company’s stock valued at $8,376,000 after purchasing an additional 252,994 shares during the period. 84.68% of the stock is owned by institutional investors.

10x Genomics Trading Down 0.4 %

NASDAQ TXG opened at $14.67 on Wednesday. The firm has a market capitalization of $1.78 billion, a P/E ratio of -9.59 and a beta of 1.84. The firm’s fifty day moving average price is $15.26 and its two-hundred day moving average price is $18.61. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $57.78.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. The company had revenue of $151.65 million for the quarter, compared to analysts’ expectations of $158.84 million. During the same period in the prior year, the firm earned ($0.51) EPS. 10x Genomics’s quarterly revenue was down 1.3% compared to the same quarter last year. On average, research analysts anticipate that 10x Genomics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TXG has been the topic of a number of research reports. Leerink Partners began coverage on shares of 10x Genomics in a research note on Tuesday, September 3rd. They issued an “outperform” rating and a $35.00 price target on the stock. UBS Group cut their price objective on shares of 10x Genomics from $25.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 30th. The Goldman Sachs Group lowered their target price on 10x Genomics from $16.00 to $14.00 and set a “sell” rating for the company in a report on Wednesday, October 30th. Canaccord Genuity Group cut their price target on 10x Genomics from $32.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, October 10th. Finally, Citigroup decreased their price objective on 10x Genomics from $35.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, October 30th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, 10x Genomics has a consensus rating of “Moderate Buy” and an average target price of $25.14.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.